Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
AntidiabeticsSUBCUTANEOUSGeneric

NOVOLOG MIX 50/50

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

Standard Dose
50 UNITS/ML;50 UNITS/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: 901 REQUIRED Marketing status: Discontinued
Summary

Approval overview NOVOLOG MIX 50/50 is listed in Drugs@FDA under application 021810 (BLA).

Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT Form and strength INJECTABLE;SUBCUTANEOUS - 50 UNITS/ML;50 UNITS/ML Sponsor NOVO NORDISK INC Submission history Latest submission status date: 2019-11-15 00:00:00.

Structured Monograph

Clinical summary

Approval overview NOVOLOG MIX 50/50 is listed in Drugs@FDA under application 021810 (BLA). Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT Form and strength INJECTABLE;SUBCUTANEOUS - 50 UNITS/ML;50 UNITS/ML Sponsor NOVO NORDISK INC Submission history Latest submission status date: 2019-11-15 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: 901 REQUIRED

Interaction Notes

  • No interaction notes stored yet.
NOVOLOG MIX 50/50 (INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT) | Drug Monograph | MedicHelpline